Integrin β3 Deficiency Results in Hypertriglyceridemia via Disrupting LPL (Lipoprotein Lipase) Secretion.


Journal

Arteriosclerosis, thrombosis, and vascular biology
ISSN: 1524-4636
Titre abrégé: Arterioscler Thromb Vasc Biol
Pays: United States
ID NLM: 9505803

Informations de publication

Date de publication:
05 2020
Historique:
pubmed: 3 4 2020
medline: 15 7 2020
entrez: 3 4 2020
Statut: ppublish

Résumé

Integrin β3 is implicated in numerous biological processes such as its relevance to blood triglyceride, yet whether β3 deficiency affects this metabolic process remains unknown. Approach and Results: We showed that the Chinese patients with β3-deficient Glanzmann thrombasthenia had a 2-fold higher serum triglyceride level together with a lower serum LPL (lipoprotein lipase) level than those with an αIIb deficiency or healthy subjects. The β3 knockout mice recapitulated these phenotypic features. The elevated plasma triglyceride level was due to impaired LPL-mediated triglyceride clearance caused by a disrupted LPL secretion. Further analysis revealed that β3 directly bound LPL via a juxtamembrane TIH (threonine isoleucine histidine) This study reveals a hypertriglyceridemia in both β3-deficient Chinese patients and mice and provides novel insights into the molecular mechanisms of the significant roles of β3 in LPL secretion and triglyceride metabolism, drawing attention to the metabolic consequences in patients with β3-deficient Glanzmann thrombasthenia.

Identifiants

pubmed: 32237906
doi: 10.1161/ATVBAHA.119.313191
doi:

Substances chimiques

Biomarkers 0
ITGB3 protein, human 0
Integrin beta Chains 0
Integrin beta3 0
Multiprotein Complexes 0
Triglycerides 0
protein kinase D EC 2.7.10.-
Protein Kinase C EC 2.7.11.13
LPL protein, human EC 3.1.1.34
Lipoprotein Lipase EC 3.1.1.34

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1296-1310

Auteurs

Bing Xiao (B)

From the State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Collaborative Innovation Center of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, China (B.X., X.X.).

Jianhua Mao (J)

State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (J.M., W.Z., Y.W., P.W., Z.R., X.X.).

Boyang Sun (B)

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China (B.S., H.L., R.Y.).

Wei Zhang (W)

State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (J.M., W.Z., Y.W., P.W., Z.R., X.X.).

Yun Wang (Y)

State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (J.M., W.Z., Y.W., P.W., Z.R., X.X.).

Pengran Wang (P)

State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (J.M., W.Z., Y.W., P.W., Z.R., X.X.).

Zheng Ruan (Z)

State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (J.M., W.Z., Y.W., P.W., Z.R., X.X.).

Wenda Xi (W)

Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China (W.X.).

Huiyuan Li (H)

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China (B.S., H.L., R.Y.).

Jingyi Zhou (J)

Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China (J.Z., Y.L., Q.D., X.W.).

Yide Lu (Y)

Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China (J.Z., Y.L., Q.D., X.W.).

Qiulan Ding (Q)

Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China (J.Z., Y.L., Q.D., X.W.).

Xuefeng Wang (X)

Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China (J.Z., Y.L., Q.D., X.W.).

Jingqiu Liu (J)

Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China (J.L., C.L.).

Jinsong Yan (J)

Department of Hematology, Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine, Second Hospital of Dalian Medical University, China (J.Y.).

Cheng Luo (C)

Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China (J.L., C.L.).

Xiaofeng Shi (X)

Department of Hematology, Affiliated Hospital of Jiangsu University, Zhenjiang, China (X.S.).

Renchi Yang (R)

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China (B.S., H.L., R.Y.).

Xiaodong Xi (X)

From the State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Collaborative Innovation Center of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, China (B.X., X.X.).
State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (J.M., W.Z., Y.W., P.W., Z.R., X.X.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH